Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

Returns on capital

Kalaris Therapeutics Inc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-55.1%

avg -18.8%

ROIC

-41.1%

avg 347.5%

ROA

-35.7%

avg -128.6%

Analysis

ROA is currently the strongest return metric at -35.7% versus its period average of -128.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andrew Oxtoby

President, Chief Executive Officer & DirectorUSD 882.04K52222.00K1.19%

Matthew Feinsod

Chief Medical OfficerUSD 665.37K55135.00K0.72%

Napoleone Ferrara

Independent Director & Co-FounderUSD 46.66K699.00K0.05%

Michael Philip Dybbs

Director & Co-FounderUSD 39K51——

Srinivas Akkaraju

Director & Co-FounderUSD 39K589.00K0.05%

Amy Vandekop

Interim Principal Accounting Officer & Corporate Controller—37——

Liisa Ann Bayko

Chief Financial Officer & Treasurer—550<0.01%

Jill E. Porter

Senior Vice President of CMC————

Kristine Curtiss

Senior Vice President of Clinical————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 20, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$6.18M

Sells

1

$12,868.80

Net Transaction Value

+$6.17M

Net buying

Most Active

AKKARAJU SRINIVAS

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 20, 26

AKKARAJU SRINIVAS

Indirect

Buy$1.2M
Mar 20, 26

Hagen Brett R

Direct

Sell$12.9K
Dec 18, 25

AKKARAJU SRINIVAS

Indirect

Buy$5M

Summary

Insiders reported 2 buys worth $6.18M and 1 sells worth $12,868.80 over the last 12 months. That adds up to net buying of $6.17M. AKKARAJU SRINIVAS was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Kalaris Therapeutics Inc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about KLRS's management, answered from reported figures.

Who manages KLRS?

Kalaris Therapeutics Inc (KLRS) lists 9 active executives. The top listed executive is Michael Philip Dybbs, Director & Co-Founder.

Are KLRS insiders buying or selling?

Recent insider activity shows net buying of $32.15M.